Reduce the risk of nonvertebral fracture in postmenopausal women with osteoporosis by using strontium ranelate
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on April 5th, 2023
|
Strontium ranelate can act on osteoblasts to enhance the efficiency of the bone formation process and inhibits the resorption process of osteoblasts. Thus, the agent had been used to manage osteoporosis. A study published in the Journal of Clinical Endocrinology & Metabolism had assessed the effectiveness of strontium ranelate in preventing fractures in patients with osteoporosis.
The study included 5091 postmenopausal women whose average age was above 75 years old. The study participants were randomly assigned to receive either placebo or 2 grams of strontium ranelate powder per day. Treatment was continued for 3 years and assessment was performed every 6 months. The study concluded that strontium ranelate helped reduce the risk of fractures of the major fragile bones (hip, wrists, pelvis, clavicle, etc.) by 19%. Stratified analysis of patients with a high risk of hip fracture shows that strontium ranelate significantly reduced the risk of hip fracture by 36%. Bone mineral density analysis showed that strontium ranelate helped increase density by 8.2% in the femur and 9.8% in the hip. Thus, strontium ranelate is an ideal addition to the current strategy to manage osteoporosis in the elderly.
The study included 5091 postmenopausal women whose average age was above 75 years old. The study participants were randomly assigned to receive either placebo or 2 grams of strontium ranelate powder per day. Treatment was continued for 3 years and assessment was performed every 6 months. The study concluded that strontium ranelate helped reduce the risk of fractures of the major fragile bones (hip, wrists, pelvis, clavicle, etc.) by 19%. Stratified analysis of patients with a high risk of hip fracture shows that strontium ranelate significantly reduced the risk of hip fracture by 36%. Bone mineral density analysis showed that strontium ranelate helped increase density by 8.2% in the femur and 9.8% in the hip. Thus, strontium ranelate is an ideal addition to the current strategy to manage osteoporosis in the elderly.